Evidence map›Paper›PMID 41796090›Full record

ArticleDiabetes, obesity & metabolism2026

Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT-1 Over 176 Weeks.

Hiddo J L Heerspink, Daniel H van Raalte, Katherine Tuttle, David Z I Cherney, Petter Bjornstad, Dachuang Cao, Georgios K Dimitriadis, Bruno Linetzky, Irina Jouravskaya, Mathijs C Bunck and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.ORCID https://orcid.org/0000-0002-3126-3730
Daniel H van RaalteAmsterdam University Medical Center, Amsterdam, the Netherlands.
Katherine TuttleProvidence Inland Northwest Health and University of Washington School of Medicine, Spokane, USA.ORCID https://orcid.org/0000-0002-2235-0103
David Z I CherneyDepartment of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-4164-0429
Petter BjornstadUniversity of Washington Medicine Diabetes Institute, Seattle, Washington, USA.
Dachuang CaoEli Lilly and Company, Indianapolis, Indiana, USA.
Georgios K DimitriadisEli Lilly and Company, Indianapolis, Indiana, USA.
Bruno LinetzkyEli Lilly and Company, Indianapolis, Indiana, USA.
Irina JouravskayaEli Lilly and Company, Indianapolis, Indiana, USA.
Mathijs C BunckEli Lilly and Company, Indianapolis, Indiana, USA.
Ryan GriffinEli Lilly and Company, Indianapolis, Indiana, USA.
Claire GerberEli Lilly and Company, Indianapolis, Indiana, USA.

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

GLP‐1obesity caretype 2 diabetesweight management

Identifiers

PMID41796090
PMCPMC13071235

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.